



## **Message to the Arrhythmogenic Cardiomyopathy Community**

LX2020 Program Update – Highlights from First Quarter 2026

May 12, 2026

Dear Advocacy Partners and PKP2-ACM community members,

We are pleased to share an [update](#) on LX2020, our investigational gene therapy for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM), based on highlights from Lexeo's first quarter 2026 results. Over the past quarter, we saw encouraging early results from participants in the ongoing study.

### **Highlights:**

- In January, Lexeo shared encouraging early results from its ongoing study of LX2020 (HEROIC).
- In this early study, LX2020 has been generally well tolerated so far, with no significant safety concerns reported in the people treated to date.

### **Next steps for the LX2020 program:**

- We anticipate sharing an update with longer-term (12-month) data from participants receiving higher doses of LX2020 in the fourth quarter of 2026.
- We expect to engage with the U.S. Food and Drug Administration (FDA) in 2026 to discuss next steps for the LX2020 program.

We are grateful to the individuals living with PKP2-ACM, their families, caregivers, investigators, and advocacy partners who make this research possible. We appreciate your continued partnership as we work to address the serious and unmet needs in arrhythmogenic cardiomyopathy.

The Lexeo Team